What is the Anti-Fibrinolytics Trialists Collaboration?
The Anti-fibrinolytics Trialists Collaboration (ATC) is an international collaboration to conduct individual patient data meta-analyses of results from randomised trials of anti-fibrinolytics versus placebo.
The ATC has been set up to address important clinical questions regarding the effects of anti-fibrinolytics that cannot be answered by individual trials or by standard meta-analyses based on aggregate data.
Click HERE to read the ACT protocol
Who are involved ?
The lead investigators of all completed and ongoing high quality trials of anti-fibrinolytics that involve 500 or more patients are invited to join the collaboration and contribute individual patient data.
The ATC is co-ordinated from Clinical Trials Unit at the London School of Hygiene & Tropical Medicine
The following trials of anti-fibrinolytics involving 500 or more patients have agreed to join the collaboration
ATACAS Trial: Aspirin and Tranexamic Acid for Coronary Artery Surgery Trial
CRASH-2: Results showed that tranexamic acid safely reduced the risk of death in bleeding trauma patients
CRASH-3: The CRASH-3 trial is the first evidence of a drug which can prevent death following Traumatic Brain Injury (TBI)
HALT-IT: Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double blind placebo controlled trial
PATCH: Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage
POISE-3: PeriOperative ISchemic Evaluation-3 Trial
ROC-TXA – Prehospital Tranexamic Acid Use for Traumatic Brain Injury
TICH-2 Trial: Tranexamic Acid for Intracerebral Haemmorhage
TRAAP: Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery
TRAAP2: TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery
Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial (ClinicalTrials.gov)
WOMAN Trial: Tranexamic acid for the treatment of postpartum haemorrhage: An international, randomised, double blind, placebo controlled trial. The WOMAN trial showed that if given within 3 hours, TXA can reduce the risk of death due to bleeding by one third
WOMAN-2 Trial: Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: an international, randomised, double-blind, placebo controlled trial
For more information, please contact:
Katharine Ker, ATC co-ordinator
Clinical Trials Unit
London School of Hygiene & Tropical Medicine
London WC1E 7HT, UK